Selexipag (Uptravi) — Coverage Criteria
Customize your policy alerts
Sign up for Health Net Policy CP.PHAR.196 alerts
Get alerted when Policy CP.PHAR.196 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity and prior authorization criteria for selexipag (Uptravi) for treatment of pulmonary arterial hypertension (PAH) across Health Net lines of business including Commercial, HIM, and Medicaid.
Added IV Uptravi 1800 mcg/10 mL formulation and criteria for use per prescribing information.
Clarified that concomitant administration with CYP2C8 inducers may require higher doses.
Revised approval duration for Commercial line of business to 12 months or duration of request, whichever is less.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.